Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03187262 · ClinicalTrials.gov registry record · Phase 2
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
A Phase 2 study of Waldenström Macroglobulinemia, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 5
- Study locations
NCT03187262: Completed Phase 2 study of Waldenström Macroglobulinemia, sponsored by Dana-Farber Cancer Institute.
NCT03187262 is a Phase 2 study of Waldenström Macroglobulinemia that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 13 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03187262, a Phase 2 study of Waldenström Macroglobulinemia, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 5
- Study locations
Study Summary
This research study is studying Daratumumab as a possible treatment for Waldenström Macroglobulinemia.
Primary Outcome
Overall Response Rate= Minor response (\>25%-50% reduction in serum IgM from baseline) + Partial Response (\>50-90% reduction in serum IgM from baseline) + Very Good Partial Response (\>90% reduction in serum IgM from baseline) + Complete Response (resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, resolution of any adenopathy or splenomegaly).
Conditions Studied
Interventions
- DRUG Daratumumab
Study Locations (5)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic - Rochester
New York
- Memorial Sloan-Kettering Cancer Center - New York
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-11-27 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 2 |
What the finished NCT03187262 record still lists
NCT03187262 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Waldenström Macroglobulinemia appearing as the primary indexed condition, and to 1 intervention - of which Daratumumab is the first listed.
NCT03187262 lists 5 locations in 4 states (Massachusetts, Minnesota, New York).
Frequently Asked Questions
What is clinical trial NCT03187262 about?
NCT03187262 is a clinical study titled "A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia". This research study is studying Daratumumab as a possible treatment for Waldenström Macroglobulinemia.
What is the current status of trial NCT03187262?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2017-11-27. Estimated completion is 2021-12-31.
What conditions does trial NCT03187262 study?
This clinical trial studies the following conditions: Waldenström Macroglobulinemia.
What interventions are being tested in trial NCT03187262?
The interventions under investigation include: Daratumumab (DRUG).
Who is sponsoring clinical trial NCT03187262?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03187262 being conducted?
This trial has 5 study locations across Massachusetts, Minnesota, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Waldenström Macroglobulinemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03187262's enrollment target sits among peer trials
13 1947th of 2000 higher than 53 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI